China’s NMPA Resumes Import of Vasudha’s Loratadine API After Rectifications
China’s National Medical Products Administration (NMPA) announced on August 20, 2025, that it had resumed...
Policy / Regulatory
InnoCare Pharma’s ICP-723 Joins China’s SPARK Project for Pediatric Solid Tumors
China’s Center for Drug Evaluation (CDE) under the National Medical Products Administration (NMPA) has announced...
China Releases Draft Guidelines for Single-Arm Oncology Trials to Support Drug Approvals
On August 20, 2025, the Center for Drug Evaluation (CDE) of the National Medical Products...
China Unveils Ten Measures to Boost Family Doctor Contract Services
In a significant move to enhance the quality and accessibility of primary healthcare, the National...
China’s NHSA Releases Interim Measures for Medical Case-Based Payment Management
The National Healthcare Security Administration (NHSA) issued the “Interim Measures for Medical Security Case-Based Payment...
China Issues Guidelines for Medical Advertisement Identification, Clarifies Scenarios and Regulations
The State Administration for Market Regulation (SAMR), in collaboration with the National Health Commission (NHC)...
FDA Launches PreCheck Program to Strengthen U.S. Pharmaceutical Supply Chain
The U.S. Food and Drug Administration (FDA) announced the launch of “FDA PreCheck” on August...
China’s NHSA Publishes Preliminary List for 2025 National Reimbursement Drug List and Commercial Insurance Innovative Drug List
China’s National Healthcare Security Administration (NHSA) released the preliminary formal review results for the 2025...
Macao Drug Administration Expands White List for Designated Medical Institutions in Cooperation Zone
The Drug Administration of the Macao Special Administrative Region (SAR) of China has announced the...
NHSA Updates Volume-Based Procurement Policy for Medical Institutions in 11th VBP Tender
The National Healthcare Security Administration (NHSA) has released Q&As on the medical institutions’ volumes filing...
Shanghai Issues New Measures to Boost Commercial Health Insurance for Biopharmaceutical Innovation
On August 6, 2025, seven Shanghai-based authorities jointly issued a notice titled “Several Measures on...
FDA Mandates Safety Labeling Changes for Opioid Pain Medications and Targets 7-OH Products
The U.S. Food and Drug Administration (FDA) is implementing new safety measures for opioid pain...
China’s NHSA Issues Rules for Instant Settlement of Medical Insurance Funds
China’s National Healthcare Security Administration (NHSA) has issued the “Interim Administrative Rules for Instant Settlement...
NMPA Seeks Public Feedback on Draft Regulations for Internet Drug and Medical Device Information Services
On July 31, 2025, China’s National Medical Products Administration (NMPA) commenced soliciting public comments on...
NMPA Updates 2025 Edition of Medical Narcotic and Psychotropic Substances Catalogs
On July 28, 2025, China’s National Medical Products Administration (NMPA), the Ministry of Public Security,...
NMPA Approves Ambroxol Hydrochloride Oral Drops for Over-the-Counter Sale
China’s National Medical Products Administration (NMPA) has approved the switch of ambroxol hydrochloride oral drops...
NHSA Announces Reforms to Centralized Drug Procurement Policies Beyond Lowest Price
The National Healthcare Security Administration (NHSA) held a press conference today on the “High-Quality Completion...
National Health Commission Launches Integrated Medical and Elder Care Demonstration Projects
On July 22, 2025, China’s National Health Commission (NHC) issued the “Work Plan for Integrated...
CDE Seeks Feedback on 96th Batch of Chemical Generic Drug Reference Standards
China’s Center for Drug Evaluation (CDE) is currently seeking public feedback on the 96th batch...
Hebei Implements Separate Payment for 57 Negotiated Drugs Starting August 1, 2025
The Hebei provincial healthcare security administration has issued the “Notice on Improving the Separate Payment...